Swedish Orphan Biovitrum AB (Publ.../ SE0000872095 /
5/24/2024 5:23:00 PM | Chg. - | Volume | Bid5:25:05 PM | Ask5:25:05 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
279.00SEK | - | 92,977 Turnover: 389,718.80 |
-Bid Size: - | -Ask Size: - | 98.65 bill.SEK | - | 37.27 |
GlobeNewswire
5/24
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Act...
GlobeNewswire
5/15
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at ...
GlobeNewswire
5/9
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
GlobeNewswire
5/6
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
5/6
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLON...
GlobeNewswire
5/1
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on...
GlobeNewswire
4/4
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination wit...
GlobeNewswire
4/3
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
GlobeNewswire
3/13
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business U...
GlobeNewswire
3/6
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
GlobeNewswire
3/6
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March...
GlobeNewswire
3/5
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cance...
GlobeNewswire
12/12/2023
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evalua...
GlobeNewswire
11/7/2023
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
GlobeNewswire
11/7/2023
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
GlobeNewswire
11/6/2023
Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia